Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377089976> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W4377089976 abstract "Objective: To compare the efficacy of vortioxetine and the serotonin-norepinephrine reuptake inhibitor (SNRI) desvenlafaxine in patients with major depressive disorder (MDD) experiencing partial response to initial treatment with a selective serotonin reuptake inhibitor (SSRI).Methods: This randomized, double-blind, active-controlled, parallel-group, 8-week study of vortioxetine (10 or 20 mg/d; n = 309) versus desvenlafaxine (50 mg/d: n = 293) was conducted from June 2020 to February 2022 in adults with a DSM-5 diagnosis of MDD who experienced partial response to SSRI monotherapy. The primary endpoint was mean change from baseline to week 8 in Montgomery-Åsberg Depression Rating Scale (MADRS) total score. Differences between groups were analyzed using mixed models for repeated measures.Results: Non-inferiority of vortioxetine versus desvenlafaxine was established in terms of mean change from baseline to week 8 in MADRS total score; however, a numeric advantage was observed in favor of vortioxetine (difference, -0.47 MADRS points [95% CI, -1.61 to 0.67]; P = .420). At week 8, significantly more vortioxetine-treated than desvenlafaxine-treated patients had achieved symptomatic and functional remission (ie, Clinical Global Impressions-Severity of Illness scale [CGI-S] score ≤ 2) (32.5% vs 24.8%, respectively; odds ratio = 1.48 [95% CI, 1.03 to 2.15]; P = .034). Vortioxetine-treated patients also experienced significantly greater improvements in daily and social functioning assessed by the Functioning Assessment Short Test (P = .009 and .045 vs desvenlafaxine, respectively) and reported significantly greater satisfaction with their medication assessed by the Quality of Life Enjoyment and Satisfaction Questionnaire (P = .044). Treatment-emergent adverse events (TEAEs) were reported in 46.1% and 39.6% of patients in the vortioxetine and desvenlafaxine groups, respectively; these were mostly mild or moderate in intensity (> 98% of all TEAEs in each group).Conclusions: Compared with the SNRI desvenlafaxine, vortioxetine was associated with significantly higher rates of CGI-S remission, better daily and social functioning, and greater treatment satisfaction in patients with MDD and partial response to SSRIs. These findings support the use of vortioxetine before SNRIs in the treatment algorithm in patients with MDD.Trial Registration: ClinicalTrials.gov Identifier: NCT04448431." @default.
- W4377089976 created "2023-05-20" @default.
- W4377089976 creator A5065553523 @default.
- W4377089976 creator A5067321782 @default.
- W4377089976 creator A5068850044 @default.
- W4377089976 creator A5069671267 @default.
- W4377089976 date "2023-05-22" @default.
- W4377089976 modified "2023-10-18" @default.
- W4377089976 title "Head-To-Head Comparison of Vortioxetine Versus Desvenlafaxine in Patients With Major Depressive Disorder With Partial Response to SSRI Therapy" @default.
- W4377089976 doi "https://doi.org/10.4088/jcp.23m14780" @default.
- W4377089976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37227402" @default.
- W4377089976 hasPublicationYear "2023" @default.
- W4377089976 type Work @default.
- W4377089976 citedByCount "0" @default.
- W4377089976 crossrefType "journal-article" @default.
- W4377089976 hasAuthorship W4377089976A5065553523 @default.
- W4377089976 hasAuthorship W4377089976A5067321782 @default.
- W4377089976 hasAuthorship W4377089976A5068850044 @default.
- W4377089976 hasAuthorship W4377089976A5069671267 @default.
- W4377089976 hasBestOaLocation W43770899761 @default.
- W4377089976 hasConcept C118552586 @default.
- W4377089976 hasConcept C126322002 @default.
- W4377089976 hasConcept C138496976 @default.
- W4377089976 hasConcept C15744967 @default.
- W4377089976 hasConcept C2778034309 @default.
- W4377089976 hasConcept C2779177272 @default.
- W4377089976 hasConcept C2780051608 @default.
- W4377089976 hasConcept C2780092697 @default.
- W4377089976 hasConcept C2780733359 @default.
- W4377089976 hasConcept C558461103 @default.
- W4377089976 hasConcept C71924100 @default.
- W4377089976 hasConcept C83849319 @default.
- W4377089976 hasConceptScore W4377089976C118552586 @default.
- W4377089976 hasConceptScore W4377089976C126322002 @default.
- W4377089976 hasConceptScore W4377089976C138496976 @default.
- W4377089976 hasConceptScore W4377089976C15744967 @default.
- W4377089976 hasConceptScore W4377089976C2778034309 @default.
- W4377089976 hasConceptScore W4377089976C2779177272 @default.
- W4377089976 hasConceptScore W4377089976C2780051608 @default.
- W4377089976 hasConceptScore W4377089976C2780092697 @default.
- W4377089976 hasConceptScore W4377089976C2780733359 @default.
- W4377089976 hasConceptScore W4377089976C558461103 @default.
- W4377089976 hasConceptScore W4377089976C71924100 @default.
- W4377089976 hasConceptScore W4377089976C83849319 @default.
- W4377089976 hasIssue "4" @default.
- W4377089976 hasLocation W43770899761 @default.
- W4377089976 hasLocation W43770899762 @default.
- W4377089976 hasOpenAccess W4377089976 @default.
- W4377089976 hasPrimaryLocation W43770899761 @default.
- W4377089976 hasRelatedWork W1572757696 @default.
- W4377089976 hasRelatedWork W1718269887 @default.
- W4377089976 hasRelatedWork W1986577602 @default.
- W4377089976 hasRelatedWork W2046080931 @default.
- W4377089976 hasRelatedWork W2351247938 @default.
- W4377089976 hasRelatedWork W2901835156 @default.
- W4377089976 hasRelatedWork W2945349547 @default.
- W4377089976 hasRelatedWork W2950488376 @default.
- W4377089976 hasRelatedWork W4212902168 @default.
- W4377089976 hasRelatedWork W4242432047 @default.
- W4377089976 hasVolume "84" @default.
- W4377089976 isParatext "false" @default.
- W4377089976 isRetracted "false" @default.
- W4377089976 workType "article" @default.